Table of Contents
- ABOUT DATAMONITOR HEALTH CARE
- About the Oncology pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the cancer market
- Related reports
- Upcoming reports
- CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
- Novel agents
- Marketed products
- Pipeline by developmental phase and indication
- The big four tumor types are still the most popular R&D targets,
although brain cancer, melanoma, ovarian cancer, pancreatic cancer and RCC
are increasing in relevance
- Pipeline split by phase
- Only 9% of the current pipeline is in late-phase development
- Pipeline by drug class
- Novel therapies constitute a greater proportion of the pipeline in the
early phases of development
- Solid tumor commonalities
- To show applicability for use in numerous indications, a pipeline drug
must affect a target that is expressed across a range of tumor types
- Key companies involved in the solid tumor pipeline
- The top three companies in terms of marketed and pipeline drugs for
solid tumors are Pfizer, AstraZeneca and Novartis
- Pfizer
- AstraZeneca
- Novartis
- CHAPTER 3 R&D APPROACH
- Classification of pipeline products
- Cytotoxics
- Antihormonal therapies
- Molecular targeted therapies
- Single-target signal transduction inhibitors
- Angiogenesis inhibitors
- Apoptosis inducers
- Cell cycle inhibitors
- Multi-targeted inhibitors
- Epigenetic modulators
- Immunotherapeutic agents
- Oncology clinical trial design
- Patient selection
- Increasingly significant in the era of targeted treatment
- Clinical trial duration
- Sufficient follow-up is necessary to establish true clinical benefit
- The advent of novel therapies
- Diversity of targeted therapies will require an evolution in
clinical trial design
- Clinical trial endpoints in oncology
- Most oncology clinical trials designate multiple endpoints
- Survival
- Quality of life
- Tumor response rates
- Toxicity
- Time to tumor progression
- CHAPTER 4 BLADDER CANCER
- Overview of bladder cancer
- Definition
- Bladder cancer remains a common tumor type in males
- Epidemiology
- Incidence of bladder cancer will rise due to an increase in
industrialization, lifestyle factors and an ageing population
- Mortality from bladder cancer is very low in the early stages,
however, rises dramatically once the tumor spreads
- Treatment of bladder cancer
- Unmet need in bladder cancer
- Summary of unmet needs
- Increase early diagnosis to enhance survival
- Agents with better routes of administration in comparison with
intravesical therapy
- A better ' standard' for advanced disease with less toxicity is needed
- Salvation of the bladder is the ideal
- Pipeline overview
- Spectrum Pharmaceuticals' EOquin (apaziquone)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Some satisfaction of unmet needs will occur, however, further research
is needed in advanced disease
- CHAPTER 5 PRIMARY BRAIN CANCER
- Overview of primary brain cancer
- Definition
- Glioma is the most common type of primary brain cancer
- Epidemiology
- Incidence of brain cancer is rising in line with the ageing
population
- Mortality from brain cancer is very high in comparison to its
incidence
- Treatment of primary brain cancer
- Unmet need in primary brain cancer
- Summary of unmet needs
- More effective chemotherapy options needed
- Blood-brain barrier may prove an obstacle to overcome
- Need for neuroprotective therapy
- Pipeline overview
- Ark Therapeutics' Cerepro (sitimagene ceradenovec)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Peregrine Pharmaceuticals' s Cotara (131I-chTNT-1/B)
- Drug overview
- Clinical trial data
- Datamonitor comments
- YM Biosciences/Biocon Biopharmaceuticals' Theraloc (nimotuzumab)
- Drug overview
- Clinical trial data
- Datamonitor comments
- NeoPharm' s cintredekin besudotox
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Temodar will retain its leading status for some time to come in the
primary brain cancer market
- CHAPTER 6 BREAST CANCER
- Overview of breast cancer
- Definition
- Breast cancer remains the most common cancer and second most common
cause of cancer-related death in women worldwide
- Epidemiology
- Incidence of breast cancer will continue to rise as lifestyles
associated with risk factors are increasingly adopted, rates of
screening increase in some countries and in line with the ageing
population
- While mortality rates are low in comparison to incidence, absolute
mortality shows breast cancer remains a leading cause of death in women
- Treatment of breast cancer
- Unmet need in breast cancer
- Summary of unmet needs
- Effective treatment for metastatic disease still remains elusive
- A wider range of treatment options is necessary for hormone
receptor-negative patients
- Elderly patients remain underserved in terms of treatment options
- More convenient and better tolerated therapies are needed
- Earlier diagnosis improves prognosis but awareness must remain high
- Pipeline overview
- Bristol-Myers Squibb' s ixabepilone (BMS-247550)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Sonus Pharmaceuticals/Bayer Schering' s Tocosol paclitaxel (emulsion
paclitaxel)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Eisai' s eribulin (E7389)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Sanofi-Aventis' s larotaxel (XRP-9881)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Ixabepilone has a real chance of fulfilling some unmet need in the
breast cancer market
- CHAPTER 7 CERVICAL CANCER
- Overview of cervical cancer
- Definition
- Cervical cancer constitutes 17% of all gynecological tumors
- Epidemiology
- Incidence will rise in line with the ageing population
- Mortality is relatively high in comparison to incidence of cervical
cancer given its propensity for early diagnosis
- Treatment of cervical cancer
- Unmet need in cervical cancer
- Summary of unmet needs
- A major healthcare burden in developing countries
- Less invasive surgery is required for early-stage tumors
- Better systemic therapy is required for metastatic and recurrent
disease
- More large-scale, randomized clinical trials are necessary to define
optimal treatment strategies across cervical cancer
- The cervical cancer pipeline is relatively sparse
- Pipeline overview
- Sanofi-Aventis/National Cancer Institute' s Tirazone (tirapazamine)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Unmet needs are unlikely to be fulfilled by the current pipeline
- CHAPTER 8 COLORECTAL CANCER
- Overview of colorectal cancer
- Definition
- Colorectal cancer is the third most common tumor type and cause of
cancer-related death in both men and women
- Epidemiology
- Incidence continues to rise with an increase in prevalence of risk
factors and the ageing population
- Mortality from colorectal cancer is relatively high due to a
tendency for later diagnosis
- Treatment of colorectal cancer
- Unmet need in colorectal cancer
- Summary of unmet needs
- Lack of identifiable risk factors and effective screening tools
- Prognosis remains poor, despite significant advances in therapy
- A high rate of disease recurrence illustrates the need for more
effective therapies
- Pipeline overview
- Pro-Pharmaceuticals' Davanat (drug delivery system)
- Drug overview
- Clinical trial data
- Datamonitor comments
- ADVENTRX Pharmaceuticals' s CoFactor (ANX-510)
- Drug overview
- Clinical trial data
- Datamonitor comments
- AstraZeneca' s Recentin (cediranib, AZD-2171)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Improvements in efficacy and prognosis are unlikely to be made by
current late-phase pipeline products
- CHAPTER 9 HEAD AND NECK CANCER
- Overview of head and neck cancer
- Definition
- Head and neck cancers comprise around 6% of all tumors worldwide
- Epidemiology
- Incidence will continue to rise in line with the ageing population
- Mortality is high due to frequent late-stage diagnosis and lack of
effective treatments
- Treatment of head and neck cancer
- Unmet need in head and neck cancer
- Summary of unmet needs
- Currently available therapies induce modest response rates
- High level of treatment-related morbidity and poor quality of life
- Early-stage diagnosis is limited, thereby compromising survival
- High economic burden
- Pipeline overview
- Regulon' s Lipoplatin (liposomal cisplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Medarex/Genmab' s zalutumumab (HuMax-EGFR)
- Drug overview
- Clinical trial data
- Datamonitor comments
- CEL-CSI' s Multikine (mixture of naturally occurring cytokines)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Viventia Biotech' s Proxinium (VB4-845)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Introgen Therapeutics' Advexin (contusugene, INGN-201)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Introgen Therapeutics' INGN-241
- Drug overview
- Clinical trial results
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Superiority over current standard therapies is unlikely to be shown by
the current pipeline
- CHAPTER 10 HEPATOCELLULAR CARCINOMA
- Overview of HCC
- Definition
- Hepatitis is a known risk factor for HCC
- Epidemiology
- Japan accounts for nearly half of all new HCC cases in the seven
major markets due to a high prevalence of hepatitis
- Mortality from HCC is high, although prognosis is steadily improving
- Treatment of HCC
- Unmet need in HCC
- Summary of unmet needs
- Curbing the increasing incidence of HCC
- Better systemic therapy is required
- Clinical trials are currently poorly designed
- HCC suffers from a relatively modest R&D interest
- Pipeline overview
- Phoenix Pharmacologics' Hepacid (pegylated arginine)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Despite impending approval of Nexavar, effective systemic therapies
are still required
- CHAPTER 11 MELANOMA
- Overview of melanoma
- Definition
- Melanoma is the least common type of skin cancer, although the most
potentially fatal
- Epidemiology
- Incidence of melanoma will continue to increase due to increasing
exposure of patients to UV light
- Mortality from melanoma is relatively low in comparison to its
incidence due to a high rate of early diagnosis
- Treatment of melanoma
- Unmet need in melanoma
- Summary of unmet needs
- Current therapeutics have a high risk to benefit ratio
- Over the past three decades there have been few significant advances
in pharmacotherapy for metastatic disease
- Early diagnosis is the key to curative treatment
- Gene profiling will help individualize treatment approaches
- Pipeline overview
- Luitpold Pharmaceuticals' Taxoprexin (DHA paclitaxel)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Vical' s Allovectin-7 (velimogene aliplasmid)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Bristol-Myers Squibb/Medarex' s ipilimumab (MDX-010)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pfizer' s tremelimumab (CP-675206)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Genta' s Genasense (oblimersen)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Progenics' s GMK (GM2-KLH)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Antigenics' s Oncophage (vitespen)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Bristol-Myers Squibb/Medarex' s MDX-1379
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- The turbulent developmental history of late-phase pipeline candidates
for melanoma means unmet needs are unlikely to be fulfilled in the near
future
- CHAPTER 12 MESOTHELIOMA
- Overview of mesothelioma
- Definition
- Mesothelioma is almost always caused by sustained exposure to
asbestos
- Epidemiology
- Forecast incidence is difficult to predict for mesothelioma,
although the cancer is relatively rare
- Survival rates for mesothelioma have improved minimally over the
years
- Treatment of mesothelioma
- Unmet need in mesothelioma
- Summary of unmet needs
- Increasing incidence and need for earlier diagnosis
- Low rate of curative surgery
- Lack of approved therapies and low R&D interest
- Pipeline overview
- Alfacell Corp' s Onconase (ranpirnase)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Onconase meets some unmet needs in terms of providing much needed
alternative treatment options
- CHAPTER 13 NON-SMALL CELL LUNG CANCER
- Overview of NSCLC
- Definition
- Lung cancer is the leading cause of cancer-related deaths in both
men and women
- Epidemiology
- The ageing population will drive a rise in NSCLC incidence in the
future
- NSCLC has a very high mortality rate
- Treatment of NSCLC
- Unmet need in NSCLC
- Summary of unmet needs
- Improved efficacy is required in the treatment of both early-stage
and advanced NSCLC
- There is a need for effective second-line treatments
- Novel therapies with improved toxicity profiles are required
- Treatment of NSCLC is in need of an overall refinement
- Clinical trial design should be re-assessed for the appropriate
evaluation of targeted therapies
- Pipeline overview
- CBA Research' s CBT-1
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pierre Fabre/Bristol-Myers Squibb' s Javlor (vinflunine)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Regulon' s Lipoplatin (liposomal cisplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Luitpold Pharmaceuticals' s Taxoprexin (DHA paclitaxel)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Cell Therapeutics' Xyotax (paclitaxel poliglumex)
- Drug overview
- Clinical trial data
- Datamonitor comments
- AstraZeneca' s Recentin (cediranib, AZD-2171)
- Drug overview
- Clinical trial data
- Datamonitor comments
- AstraZeneca' s Zactima (vandetanib, ZD6474)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Regeneron/Sanofi-Aventis aflibercept (VEGF Trap)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Biomira/Merck Serono' s Stimuvax (BLP-25)
- Drug overview
- Clinical trial data
- Datamonitor comments
- GlaxoSmithKline' s MAGE-A3 ASCI (GSK-1572932A)
- Drug overview
- Clinical trial results
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Unmet needs are unlikely to be fulfilled by the current pipeline
- CHAPTER 14 OVARIAN CANCER
- Overview of ovarian cancer
- Definition
- Ovarian cancer is the most frequent cause of cancer-related death
from gynecological malignancies
- Epidemiology
- Ovarian cancer is a disease primarily of postmenopausal women,
therefore incidence will continue to rise in line with the ageing
population
- Mortality from ovarian cancer is relatively high in comparison with
its incidence due to a high rate of diagnosis at Stage III disease
- Treatment of ovarian cancer
- Unmet need in ovarian cancer
- Summary of unmet needs
- Earlier rates of diagnosis are needed
- Less invasive surgical techniques are required
- More effective systemic therapies are needed across multiple lines
of treatment
- Increase level of R&D interest
- Pipeline overview
- BioNumerik' s Karenitecin (BNP-1350)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Cell Therapeutics/Novartis' s Xyotax (paclitaxel poliglumex)
- Drug overview
- Clinical trial data
- Datamonitor comments
- PharmaMar/Johnson & Johnson' s Yondelis (trabectedin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Novartis' s patupilone (EPO-906)
- Drug overview
- Clinical trial data
- Datamonitor comments
- ViRexx Medical Corp/Unither Pharmaceuticals' OvaRex (oregovomab)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Telik' s Telcyta (canfosfamide, TLK-286)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Marshall Edward' s phenoxodiol
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Unmet needs in ovarian cancer will be fulfilled to some extent by
means of providing numerous alternative treatment options
- CHAPTER 15 PANCREATIC CANCER
- Overview of pancreatic cancer
- Definition
- Pancreatic cancer represents a major health issue in the developed
world
- Epidemiology
- Absolute incidence of pancreatic cancer correlates to population
size, therefore incidence will continue to rise as a reflection of the
ageing population
- Mortality from pancreatic cancer is nearly equal to its incidence
- Treatment of pancreatic cancer
- Unmet need in pancreatic cancer
- Summary of unmet need
- Associated with exceptionally poor survival rates
- Earlier rates of diagnosis are desperately needed in order to boost
survival
- A lack of effective systemic therapies exists, therefore an
increased level of R&D interest is needed
- Pipeline overview
- Sanofi-Aventis' s larotaxel (XRP-9881)
- Drug overview
- Clinical trial data
- Datamonitor comments
- GenVec' s TNFerade (TNF-alpha gene therapy)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pfizer' s axitinib (AG-13736)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pharmexa/GemVax' s GV-1001
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- All four late-phase pipeline products show some potential to fulfill
unmet needs in the pancreatic cancer market
- CHAPTER 16 PROSTATE CANCER
- Overview of prostate cancer
- Definition
- Prostate cancer remains the most common cancer and second cause of
cancer-related death in men worldwide
- Epidemiology
- Incidence of prostate cancer continues to rise with advances in
screening procedures
- Mortality from prostate cancer is relatively low given the high
propensity for early diagnosis
- Treatment of prostate cancer
- Unmet need in prostate cancer
- Summary of unmet needs
- Side effects from antihormonal therapies may affect compliance
- Alternative treatment options are needed for hormone-refractory
patients
- Greater R&D interest is needed in terms of innovative therapies
- Pipeline overview
- Dendreon' s Provenge (sipuleucel-T)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Ferring/Astellas' s degarelix
- Drug overview
- Clinical trial data
- Datamonitor comments
- Novacea/Schering-Plough' s Asentar (calcitriol, DN-101)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Spectrum Pharmaceuticals/GPC Biotech' s Orplatna (satraplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Sanofi-Aventis' s XRP-6258
- Drug overview
- Clinical trial data
- Datamonitor comments
- Abbott' s Xinlay (atrasentan)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Cell Genesys' s GVAX (CG-8123)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Prostate cancer' s high patient potential means R&D interest is
relatively high and unmet needs have a higher chance of being fulfilled
- CHAPTER 17 RENAL CELL CARCINOMA
- Overview of renal cell carcinoma
- Definition
- Renal cell carcinoma has formed a popular R&D indication in
recent times
- Epidemiology
- Incidence of renal cell carcinoma will continue to rise in line with
the ageing population, increasing rates of obesity and more frequent
diagnosis following imaging procedures
- Mortality is high in late-stage RCC patients
- Treatment of RCC
- Unmet need in RCC
- Summary of unmet need
- Adjuvant therapy to prevent relapse following surgery in Stage I-III
patients
- More systemic therapies required to provide options in later lines
of treatment
- Non-clear cell RCC subtypes must be the focus of future therapies
- Pipeline overview
- Wilex' s Rencarex (WX-G250)
- Drug overview
- Clinical trial data
- Datamonitor comments
- GlaxoSmithKline' s pazopanib (GW-786034)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Antigenics' Oncophage (vitespen)
- Drug overview
- Clinical trial data
- Datamonitor comments
- LipoNova' s Reniale
- Drug overview
- Clinical trial data
- Datamonitor comments
- Oxford Biomedica' s TroVax (MVA-h5T4)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Potential adjuvant therapies are in development, while the need for
multiple products in later treatment settings may also be fulfilled
- CHAPTER 18 SARCOMAS
- Overview of sarcoma
- Definition
- Sarcomas represent a diverse group of malignancies
- Epidemiology
- Given the numerous subtypes of sarcoma, crude incidence rates are
not readily available
- Evolution of multimodality treatment for sarcomas of the bone has
improved survival, while early diagnosis of soft tissue sarcoma allows
for relatively high survival
- Treatment of sarcoma
- Sarcoma of the bone
- Soft tissue sarcoma
- Unmet need in sarcoma
- Summary of unmet need
- Better classification methods are needed
- Greater range of treatment options following surgery and more
efficacious agents for advanced disease are necessary
- Pipeline overview
- IDM Pharma' s Junovan (liposomal mifamurtide)
- Drug overview
- Clinical trial data
- Datamonitor comments
- PharmaMar/Johnson & Johnson' s Yondelis (trabectedin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Novartis' s Tasigna (nilotinib)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Current pipeline drugs will go some way toward satisfying the need for
a greater range of treatment options in sarcoma
- CHAPTER 19 SMALL CELL LUNG CANCER
- Overview of SCLC
- Definition
- SCLC is the most aggressive lung tumor, although the most responsive
to chemotherapy and radiotherapy
- Epidemiology
- Incidence of SCLC is decreasing in part due to declining rates of
cigarette smoking
- Five-year survival rates for SCLC are poor, although slowly improving
- Treatment of SCLC
- Unmet need in SCLC
- Summary of unmet needs
- Need for earlier diagnosis
- Strong association with smoking
- Low rate of curative surgery
- Lack of efficacious systemic therapies
- Low R&D interest
- Pipeline overview
- Poniard Pharmaceuticals' Nexplatin (picoplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Nexplatin could fulfill some unmet need in a treatment setting with
few alternative treatment options
- CHAPTER 20 THYROID CANCER
- Overview of thyroid cancer
- Definition
- Thyroid cancer occurs more frequently in women and at a younger age
- Epidemiology
- Incidence of thyroid cancer is rising due to increasing use of
ultrasound to detect small tumors
- Thyroid cancer is one of the least deadly tumor types
- Treatment of thyroid cancer
- Unmet need in thyroid cancer
- Summary of unmet need
- R&D interest is exceedingly low
- Few alternative treatment options exist upon disease recurrence
- Pipeline overview
- Pfizer' s axitinib (AG-13736)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Axitinib could form a viable therapy where few alternative treatment
options exist
- APPENDIX A
- Bibliography
- List of tables
- List of figures
- List of abbreviations
- Methodology
- Datamonitor forecast methodology
- Epidemiology forecasts
- Product forecasts
- Datamonitor drug assessment summary
- APPENDIX B
- About Datamonitor
- About Datamonitor Healthcare
- Datamonitor Healthcare' s therapy area capabilities
- About the Disease analysis team
- Disclaimer
- List of Tables
- Table 1: Novel agents in preregistration for solid tumors, 2007
- Table 2: Novel cytotoxics in Phase III development for solid tumors,
2007
- Table 3: Novel miscellaneous agents in Phase III development for solid
tumors, 2007
- Table 4: Novel targeted therapies in Phase III development for solid
tumors, 2007
- Table 5: Novel therapeutic vaccines in Phase III development for solid
tumors, 2007
- Table 6: Marketed products in preregistration for solid tumors, 2007
- Table 7: Marketed agents in Phase III development for solid tumors,
2007
- Table 8: Marketed targeted therapies in Phase III development for
solid tumors, 2007
- Table 9: Solid tumor pipeline split by phase and indication, 2007
- Table 10: Solid tumor pipeline drugs being developed for seven or more
indications, 2007
- Table 11: Pfizer' s marketed cancer portfolio, 2007
- Table 12: Pfizer' s solid tumor pipeline portfolio, 2007
- Table 13: AstraZeneca' s marketed cancer portfolio, 2007
- Table 14: AstraZeneca' s solid tumor pipeline portfolio, 2007
- Table 15: Novartis' s marketed cancer portfolio, 2007
- Table 16: Novartis' s solid tumor pipeline portfolio, 2007
- Table 17: Crude incidence rate of bladder cancer per 100,000
population in the seven major pharmaceutical markets, 2002
- Table 18: Estimated incidence of bladder cancer in the seven major
pharmaceutical markets, 2007-15
- Table 19: Five-year survival rates by stage of bladder cancer,
1975-2000
- Table 20: Marketed drugs in development for bladder cancer, 2007
- Table 21: Phase II/III bladder cancer pipeline, 2007
- Table 22: Forecasting assumptions for EOquin in bladder cancer across
the seven major markets, 2007
- Table 23: EOquin sales forecast for bladder cancer, 2007-16 ($m)
- Table 24: Estimated incidence of brain cancer in the seven major
pharmaceutical markets, 2007-15
- Table 25: Marketed drugs in development for brain cancer, 2007
- Table 26: Phase III primary brain cancer pipeline, 2007
- Table 27: Phase II primary brain cancer pipeline, 2007 (cytotoxics and
miscellaneous)
- Table 28: Phase II primary brain cancer pipeline, 2007 (targeted
therapies)
- Table 29: Forecasting assumptions for pipeline brain cancer products
across the seven major markets, 2007
- Table 30: Pipeline brain cancer product sales forecasts, 2007-16 ($m)
- Table 31: Estimated incidence of breast cancer in the seven major
pharmaceutical markets, 2007-15
- Table 32: Eight-year survival rates by stage of breast cancer
- Table 33: Marketed drugs in development for breast cancer, 2007
- Table 34: Preregistration breast cancer pipeline, 2007
- Table 35: Phase III breast cancer pipeline, 2007
- Table 36: Phase II breast cancer pipeline, 2007 (cytotoxics)
- Table 37: Phase II breast cancer pipeline, 2007 (targeted therapies)
- Table 38: Phase II breast cancer pipeline, 2007 (miscellaneous)
- Table 39: Phase III development of eribulin in breast cancer, 2007
- Table 40: Phase I/II development of larotaxel in breast cancer, 2007
- Table 41: Forecasting assumptions for pipeline breast cancer products
across the seven major markets, 2007
- Table 42: Pipeline breast cancer product sales forecasts across the
seven major markets, 2007-16 ($m)
- Table 43: Estimated incidence of cervical cancer in the seven major
pharmaceutical markets, 2007-15
- Table 44: Marketed drugs in development for cervical cancer, 2007
- Table 45: Phase II/III cervical cancer pipeline, 2007
- Table 46: Clinical development of Tirazone in cervical cancer, 2007
- Table 47: Forecasting assumptions for Tirazone in cervical cancer
across the seven major markets, 2007
- Table 48: Tirazone sales forecast for cervical cancer, 2007-16 ($m)
- Table 49: Estimated incidence of colorectal cancer in the seven major
pharmaceutical markets, 2007-15
- Table 50: Marketed drugs in development for colorectal cancer, 2007
- Table 51: Late-phase colorectal cancer pipeline, 2007
- Table 52: Phase II colorectal cancer pipeline, 2007 (cytotoxics and
miscellaneous)
- Table 53: Phase II colorectal cancer pipeline, 2007 (targeted
therapies)
- Table 54: Clinical development for Davanat in colorectal cancer, 2007
- Table 55: Clinical development for CoFactor in colorectal cancer, 2007
- Table 56: Clinical development for Recentin in colorectal cancer, 2007
- Table 57: Forecasting assumptions for pipeline colorectal cancer
products across the seven major markets, 2007
- Table 58: Pipeline colorectal cancer product sales forecasts, 2007-16
($m)
- Table 59: Risk factors for subtypes of head and neck cancer
- Table 60: Estimated incidence of head and neck cancer in the seven
major pharmaceutical markets, 2007-15
- Table 61: Marketed drugs in development for head and neck cancer, 2007
- Table 62: Phase III head and neck cancer pipeline, 2007
- Table 63: Phase II head and neck cancer pipeline, 2007
- Table 64: Clinical development for zalutumumab in head and neck
cancer, 2007
- Table 65: Clinical development for Proxinium in head and neck cancer,
2007
- Table 66: Clinical development for Advexin in head and neck cancer,
2007
- Table 67: Forecasting assumptions for pipeline head and neck cancer
products across the seven major markets, 2007 (1 of 2)
- Table 68: Forecasting assumptions for pipeline head and neck cancer
products across the seven major markets, 2007 (2 of 2)
- Table 69: Pipeline head and neck cancer product sales forecasts,
2007-16 ($m)
- Table 70: Estimated incidence of HCC in the seven major pharmaceutical
markets, 2007-15
- Table 71: Marketed drugs in development for HCC, 2007
- Table 72: Phase III HCC pipeline, 2007
- Table 73: Phase II HCC pipeline, 2007
- Table 74: Forecasting assumptions for Hepacid in HCC across the seven
major markets, 2007
- Table 75: Hepacid sales forecast for HCC, 2007-16 ($m)
- Table 76: Estimated incidence of melanoma in the seven major
pharmaceutical markets, 2007-15
- Table 77: Stage distribution of melanoma in the US, 1975-2000
- Table 78: Five-year survival rates by pathologic stage for melanoma,
2001
- Table 79: Marketed drugs in development for melanoma, 2007
- Table 80: Phase III melanoma pipeline, 2007
- Table 81: Phase II melanoma pipeline, 2007 (miscellaneous)
- Table 82: Phase II melanoma pipeline, 2007 (targeted therapies)
- Table 83: Phase II melanoma pipeline, 2007 (vaccines)
- Table 84: Clinical development of Allovectin-7 in melanoma, 2007
- Table 85: Clinical development of ipilimumab in melanoma, 2007
- Table 86: Clinical development of tremelimumab in melanoma, 2007
- Table 87: Forecasting assumptions for pipeline melanoma products
across the seven major markets, 2007 (1 of 2)
- Table 88: Forecasting assumptions for pipeline melanoma products
across the seven major markets, 2007 (2 of 2)
- Table 89: Pipeline melanoma product sales forecasts, 2007-16 ($m)
- Table 90: Epidemiologic features of malignant mesothelioma, 2005
- Table 91: Marketed drugs in development for mesothelioma, 2007
- Table 92: Phase II/III mesothelioma pipeline, 2007
- Table 93: Forecasting assumptions for Onconase in mesothelioma across
the seven major markets, 2007
- Table 94: Onconase sales forecast for mesothelioma, 2007-16 ($m)
- Table 95: Estimated incidence of NSCLC in the seven major
pharmaceutical markets, 2007-15
- Table 96: Marketed drugs in development for NSCLC, 2007
- Table 97: Phase III NSCLC pipeline, 2007
- Table 98: Phase II NSCLC pipeline, 2007 (miscellaneous)
- Table 99: Phase II NSCLC pipeline, 2007 (targeted therapies, 1 of 2)
- Table 100: Phase II NSCLC pipeline, 2007 (targeted therapies, 2 of 2)
- Table 101: Clinical development for Javlor in NSCLC, 2007
- Table 102: Clinical development for Xyotax in NSCLC, 2007
- Table 103: Summary of Xyotax Phase III STELLAR trial results
- Table 104: Clinical development for Recentin in NSCLC, 2007
- Table 105: Clinical development for Zactima in NSCLC, 2007
- Table 106: Clinical development for Stimuvax in NSCLC, 2007
- Table 107: Forecasting assumptions for pipeline NSCLC products across
the seven major markets, 2007 (1 of 3)
- Table 108: Forecasting assumptions for pipeline NSCLC products across
the seven major markets, 2007 (2 of 3)
- Table 109: Forecasting assumptions for pipeline NSCLC products across
the seven major markets, 2007 (3 of 3)
- Table 110: Pipeline NSCLC product sales forecasts, 2007-16 ($m)
- Table 111: Estimated incidence of ovarian cancer in the seven major
pharmaceutical markets, 2007-15
- Table 112: Stage distribution at diagnosis
- Table 113: Five-year survival rate by stage of ovarian cancer
- Table 114: Marketed drugs in development for ovarian cancer, 2007
- Table 115: Phase III ovarian cancer pipeline, 2007
- Table 116: Phase II ovarian cancer pipeline, 2007 (miscellaneous)
- Table 117: Phase II ovarian cancer pipeline, 2007 (targeted therapies)
- Table 118: Clinical development of patupilone in ovarian cancer, 2007
- Table 119: Phase III trials investigating Telcyta for ovarian cancer,
2007
- Table 120: Forecasting assumptions for pipeline ovarian cancer
products across the seven major markets, 2007 (1 of 2)
- Table 121: Forecasting assumptions for pipeline ovarian cancer
products across the seven major markets, 2007 (2 of 2)
- Table 122: Pipeline ovarian cancer product sales forecasts, 2007-16
($m)
- Table 123: Estimated incidence of pancreatic cancer in the seven major
pharmaceutical markets, 2007-15
- Table 124: Marketed drugs in development for pancreatic cancer, 2007
- Table 125: Phase III pancreatic cancer pipeline, 2007
- Table 126: Phase II pancreatic cancer pipeline, 2007 (miscellaneous)
- Table 127: Phase II pancreatic cancer pipeline, 2007 (targeted
therapies)
- Table 128: Phase I trial results for larotaxel in advanced solid tumors
- Table 129: Clinical development of GV-1001 in pancreatic cancer, 2007
- Table 130: Forecasting assumptions for pipeline pancreatic cancer
products across the seven major markets, 2007
- Table 131: Pipeline pancreatic cancer product sales forecasts, 2007-16
($m)
- Table 132: Estimated incidence of prostate cancer in the seven major
pharmaceutical markets, 2007-15
- Table 133: Stage distribution of prostate cancer and five-year
survival rates in the US
- Table 134: Marketed drugs in development for prostate cancer, 2007
- Table 135: Late-phase prostate cancer pipeline, 2007
- Table 136: Phase II prostate cancer pipeline, 2007 (cytotoxics)
- Table 137: Phase II prostate cancer pipeline, 2007 (miscellaneous)
- Table 138: Phase II prostate cancer pipeline, 2007 (targeted
therapies, 1 of 2)
- Table 139: Phase II prostate cancer pipeline, 2007 (targeted
therapies, 2 of 2)
- Table 140: Clinical development of degarelix in prostate cancer, 2007
- Table 141: Clinical development of GVAX in prostate cancer, 2007
- Table 142: Phase II results for GVAX monotherapy in HRPC
- Table 143: Forecasting assumptions for pipeline prostate cancer
products across the seven major markets, 2007 (1 of 2)
- Table 144: Forecasting assumptions for pipeline prostate cancer
products across the seven major markets, 2007 (2 of 2)
- Table 145: Pipeline prostate cancer product sales forecasts, 2007-16
($m)
- Table 146: Estimated incidence of RCC in the seven major
pharmaceutical markets, 2007-15
- Table 147: Five-year survival rate by stage of RCC, 2004
- Table 148: Stage of RCC at diagnosis
- Table 149: Marketed drugs in development for RCC, 2007
- Table 150: Phase III RCC pipeline, 2007
- Table 151: Phase II RCC pipeline, 2007 (miscellaneous)
- Table 152: Phase II RCC pipeline, 2007 (targeted therapies)
- Table 153: Phase II development for TroVax in RCC
- Table 154: Forecasting assumptions for pipeline RCC products across
the seven major markets, 2007 (1 of 2)
- Table 155: Forecasting assumptions for pipeline RCC products across
the seven major markets, 2007 (2 of 2)
- Table 156: Pipeline RCC product sales forecasts, 2007-16 ($m)
- Table 157: Types of sarcoma of the bone
- Table 158: Proportion of soft tissue sarcomas based on site of
malignancy
- Table 159: Estimated incidence of osteosarcoma in the seven major
pharmaceutical markets, 2007-15
- Table 160: Estimated incidence of soft tissue sarcoma in the seven
major pharmaceutical markets, 2007-15
- Table 161: Estimated incidence of GIST in the seven major
pharmaceutical markets, 2007-15
- Table 162: Five-year survival rates by stage of soft tissue sarcoma
- Table 163: Marketed drugs in development for sarcoma, 2007
- Table 164: Late-phase sarcoma pipeline, 2007
- Table 165: Phase II sarcoma pipeline, 2007
- Table 166: Forecasting assumptions for pipeline sarcoma products
across the seven major markets, 2007
- Table 167: Pipeline sarcoma product sales forecasts, 2007-16 ($m)
- Table 168: Estimated incidence of SCLC in the seven major
pharmaceutical markets, 2007-15
- Table 169: Marketed drugs in development for SCLC, 2007
- Table 170: Phase III SCLC pipeline, 2007
- Table 171: Phase II SCLC pipeline, 2007
- Table 172: Forecasting assumptions for Nexplatin in SCLC across the
seven major markets, 2007
- Table 173: Nexplatin sales forecast for SCLC, 2007-16 ($m)
- Table 174: Estimated incidence of thyroid cancer in the seven major
pharmaceutical markets, 2007-15
- Table 175: Five-year survival rates by stage of thyroid cancer
- Table 176: Marketed drugs in development for thyroid cancer, 2007
- Table 177: Phase II/III thyroid cancer pipeline, 2007
- Table 178: Phase II development of axitinib in thyroid cancer, 2007
- Table 179: Forecasting assumptions for axitinib in thyroid cancer
across the seven major markets, 2007
- Table 180: Axitinib sales forecast for thyroid cancer, 2007-16 ($m)
- Table 181: List of abbreviations (1 of 2)
- Table 182: List of abbreviations (2 of 2)
- Table 183: Datamonitor drug assessment parameters
- List of Figures
- Figure 1: Solid tumor pipeline split by phase and indication, 2007
- Figure 2: Extent of pipeline activity in relation to incidence of
cancer, 2007
- Figure 3: Solid tumor pipeline split by phase, 2007
- Figure 4: Late-phase solid tumor pipeline by drug class, 2007
- Figure 5: Phase II solid tumor pipeline by drug class, 2007
- Figure 6: Phase I solid tumor pipeline by drug class, 2007
- Figure 7: Incidence and mortality from bladder cancer in 2007 and 2015
across the seven major markets
- Figure 8: Summary of unmet needs in the bladder cancer market
- Figure 9: Phase II study investigating EOquin in recurrent
non-invasive bladder cancer
- Figure 10: EOquin sales forecast for bladder cancer, 2007-16 ($m)
- Figure 11: Datamonitor drug assessment summary for EOquin in bladder
cancer, 2007
- Figure 12: Incidence and mortality from brain cancer in 2007 and 2015
across the seven major markets
- Figure 13: Summary of unmet needs in the primary brain cancer market
- Figure 14: Phase II trial investigating Cerepro in primary and
recurrent glioma patients
- Figure 15: Phase II trial investigating Cotara in newly diagnosed or
recurrent glioma patients
- Figure 16: Phase II trial investigating Theraloc in pediatric pontine
glioma patients
- Figure 17: Phase III trial investigating cintredekin in glioblastoma
multiforme patients
- Figure 18: Pipeline brain cancer product sales forecasts, 2007-16 ($m)
- Figure 19: Datamonitor drug assessment summary for the pipeline brain
cancer products, 2007
- Figure 20: Incidence and mortality from breast cancer in 2007 and 2015
across the seven major markets
- Figure 21: Summary of unmet needs in the breast cancer market
- Figure 22: Phase III trial investigating ixabepilone and Xeloda in
refractory breast cancer
- Figure 23: Phase III study investigating first- or second-line Tocosol
paclitaxel versus standard paclitaxel in metastatic breast cancer
- Figure 24: Phase II study investigating eribulin in
chemotherapy-refractory advanced breast cancer patients
- Figure 25: Phase II results investigating larotaxel in non-taxane
resistant and resistant breast cancer patients
- Figure 26: Pipeline breast cancer product sales forecasts across the
seven major markets, 2007-16 ($m)
- Figure 27: Datamonitor drug assessment summary for the pipeline breast
cancer products, 2007
- Figure 28: Incidence and mortality from cervical cancer in 2007 and
2015 across the seven major markets
- Figure 29: Summary of unmet needs in the cervical cancer market
- Figure 30: Phase II trial investigating Tirazone and cisplatin in
metastatic cervical cancer patients (Maluf et al.)
- Figure 31: Phase II trial investigating Tirazone and cisplatin in
metastatic cervical cancer patients (Smith et al.)
- Figure 32: Tirazone sales forecast for cervical cancer, 2007-16 ($m)
- Figure 33: Datamonitor drug assessment summary for Tirazone in
cervical cancer, 2007
- Figure 34: Incidence and mortality from colorectal cancer in 2007 and
2015 across the seven major markets
- Figure 35: Improving survival with newer drug regimens
- Figure 36: Summary of unmet needs in the colorectal cancer market
- Figure 37: Interim data from Phase II DAVFU-006 trial
- Figure 38: Phase II trial investigating first-line CoFactor with
5-fluorouracil in metastatic colorectal cancer patients
- Figure 39: Pipeline colorectal cancer product sales forecasts, 2007-16
($m)
- Figure 40: Datamonitor drug assessment summary for the pipeline
colorectal cancer products, 2007
- Figure 41: Incidence and mortality from oral cavity cancer in 2007 and
2015 across the seven major markets
- Figure 42: Incidence and mortality from laryngeal cancer in 2007 and
2015 across the seven major markets
- Figure 43: Summary of unmet needs in the head and neck cancer market
- Figure 44: Phase I/II trial results for zalutumumab in patients with
recurrent squamous cell head and neck cancer
- Figure 45: Phase II trial and follow-up results for neoadjuvant
Multikine in head and neck cancer
- Figure 46: Phase I dose-escalation trial for Proxinium in advanced
head and neck cancer
- Figure 47: Phase II trial for Advexin in recurrent squamous cell head
and neck cancer
- Figure 48: Pipeline head and neck cancer product sales forecasts,
2007-16 ($m)
- Figure 49: Datamonitor drug assessment summary for the pipeline head
and neck cancer products, 2007
- Figure 50: Five-year survival rates for liver and intrahepatic bile
duct cancer, 1975-98
- Figure 51: Summary of unmet needs in the HCC market
- Figure 52: Phase II trial investigating Hepacid in advanced HCC
patients
- Figure 53: Hepacid sales forecast for HCC, 2007-16 ($m)
- Figure 54: Datamonitor drug assessment summary for Hepacid in HCC, 2007
- Figure 55: Incidence and mortality from melanoma in 2007 and 2015
across the seven major markets
- Figure 56: Summary of unmet needs in the melanoma market
- Figure 57: Phase II trial investigating first-line Taxoprexin in
metastatic melanoma
- Figure 58: Phase II results investigating high-dose Allovectin-7 in
recurrent or unresponsive Stage III/IV melanoma
- Figure 59: Phase II results investigating varying doses of ipilimumab
in unresectable Stage III/IV melanoma patients
- Figure 60: Analysis of data from five Phase I/II clinical trials
investigating ipilimumab in Stage III/IV melanoma
- Figure 61: Phase II results investigating second-line tremelimumab in
Stage III/IV melanoma patients
- Figure 62: Long-term follow-up results from a Phase III trial
investigating dacarbazine with or without Genasense in metastatic melanoma
- Figure 63: Phase III trial investigating adjuvant GMK versus high-dose
interferon-alfa in Stage IIb/III resected melanoma
- Figure 64: Phase III trial results comparing adjuvant Oncophage to
standard therapy in Stage IV melanoma patients
- Figure 65: Phase II trial results investigating a combination of
ipilimumab and MDX-1379 in Stage IV melanoma patients
- Figure 66: Pipeline melanoma product sales forecasts, 2007-16 ($m)
- Figure 67: Datamonitor drug assessment summary for the pipeline
melanoma products, 2007
- Figure 68: Five-year survival rates for mesothelioma in the US, 1975-98
- Figure 69: Summary of unmet needs in the mesothelioma market
- Figure 70: Interim Phase III results investigating doxorubicin with or
without Onconase in mesothelioma patients
- Figure 71: Onconase sales forecast for mesothelioma, 2007-16 ($m)
- Figure 72: Datamonitor drug assessment summary for Onconase in
mesothelioma, 2007
- Figure 73: Incidence and mortality from NSCLC in 2007 and 2015 across
the seven major markets
- Figure 74: Summary of unmet needs in the NSCLC market
- Figure 75: Phase III trial investigating second-line Javlor versus
Taxotere in advanced NSCLC
- Figure 76: Phase III trial investigating first-line Lipoplatin and
Gemzar in inoperable or metastatic NSCLC
- Figure 77: Clinical data for Taxoprexin in the first-line treatment of
advanced NSCLC
- Figure 78: Phase II trial investigating a first-line combination of
Zactima, carboplatin and paclitaxel in advanced NSCLC patients
- Figure 79: Phase II trial investigating second-line Taxotere with or
without Zactima alone in advanced NSCLC
- Figure 80: Phase II trial evaluating Zactima monotherapy in the
second/third-line NSCLC treatment setting
- Figure 81: Preliminary Phase II trial results for third-line
aflibercept in advanced NSCLC patients
- Figure 82: Phase II trial evaluating MAGE-A3 as adjuvant therapy in
resected Stage IB/II NSCLC
- Figure 83: Pipeline NSCLC product sales forecasts, 2007-16 ($m)
- Figure 84: Datamonitor drug assessment summary for the pipeline NSCLC
products, 2007
- Figure 85: Incidence and mortality from ovarian cancer in 2007 and
2015 across the seven major markets
- Figure 86: Summary of unmet needs in the ovarian cancer market
- Figure 87: Phase II trial results investigating Xyotax in newly
diagnosed Stage III/IV ovarian cancer patients
- Figure 88: Phase II results investigating second/third-line Yondelis
in advanced ovarian cancer patients (McMeekin et al., 2005)
- Figure 89: Phase II results investigating second/third-line Yondelis
in advanced ovarian cancer patients (Sessa et al., 2005)
- Figure 90: Phase I/II trial investigating second-line patupilone in
refractory or relapsed advanced ovarian cancer
- Figure 91: Phase II randomized trial investigating front-line
carboplatin and paclitaxel with or without OvaRex in advanced ovarian
cancer
- Figure 92: Results from the Phase III ASSIST-1 study
- Figure 93: Results from the Phase III ASSIST-3 study
- Figure 94: Preliminary Phase IIa results investigating a second-line
combination of phenoxodiol with either paclitaxel or cisplatin
- Figure 95: Pipeline ovarian cancer product sales forecasts, 2007-16
($m)
- Figure 96: Datamonitor drug assessment summary for the pipeline
ovarian cancer products, 2007
- Figure 97: Incidence and mortality from pancreatic cancer in 2007 and
2015 across the seven major markets
- Figure 98: Summary of unmet needs in the pancreatic cancer market
- Figure 99: Interim results from the PACT trial
- Figure 100: Phase II trial investigating first-line Gemzar and
axitinib in advanced pancreatic cancer
- Figure 101: Phase I/II trial results investigating GV-1001 in
unresectable pancreatic cancer
- Figure 102: Pipeline pancreatic cancer product sales forecasts,
2007-16 ($m)
- Figure 103: Datamonitor drug assessment summary for the pipeline
pancreatic cancer products, 2007
- Figure 104: Incidence and mortality from prostate cancer in 2007 and
2015 across the seven major markets
- Figure 105: Summary of unmet needs in the prostate cancer market
- Figure 106: Results from the Phase III D9901 study
- Figure 107: Analysis of patient subgroup from D9901 and D9902A who
received Taxotere following Provenge or placebo
- Figure 108: Phase II/III ASCENT study results
- Figure 109: Phase III SPARC trial results
- Figure 110: Meta-analysis of pooled results from two Phase III results
investigating Xinlay in metastatic HRPC
- Figure 111: Pipeline prostate cancer product sales forecasts, 2007-16
($m)
- Figure 112: Datamonitor drug assessment summary for the pipeline
prostate cancer products, 2007
- Figure 113: Summary of unmet needs in the RCC market
- Figure 114: Rencarex monotherapy in a Phase II study in metastatic RCC
- Figure 115: Rencarex and interferon-alfa in a Phase II study in Stage
IV RCC
- Figure 116: Final analysis of a Phase II trial investigating
single-agent pazopanib in cytokine-naïve and refractory patients
- Figure 117: Phase III trial data investigating adjuvant Reniale versus
no further treatment
- Figure 118: Phase II trial investigating TroVax as a single agent or
in combination with interleukin-2 or interferon-alfa
- Figure 119: Pipeline RCC product sales forecasts, 2007-16 ($m)
- Figure 120: Datamonitor drug assessment summary for the pipeline RCC
products, 2007
- Figure 121: Summary of unmet needs in the sarcoma market
- Figure 122: Phase III INT-0133 study design
- Figure 123: Phase III INT-0133 study results
- Figure 124: Results from a pivotal Phase II study comparing two dosing
regimens of Yondelis in refractory soft tissue sarcoma
- Figure 125: Phase I trial investigating Tasigna alone or in
combination with Gleevec in Gleevec-resistant GIST patients
- Figure 126: Pipeline sarcoma product sales forecasts, 2007-16 ($m)
- Figure 127: Datamonitor drug assessment summary for the pipeline
sarcoma products, 2007
- Figure 128: Datamonitor drug assessment summary for the pipeline GIST
products, 2007
- Figure 129: Five-year survival rates of NSCLC and SCLC in the US,
1975-2002
- Figure 130: Summary of unmet needs in the SCLC market
- Figure 131: Phase II trial investigating second-line Nexplatin in SCLC
- Figure 132: Nexplatin sales forecast for SCLC, 2007-16 ($m)
- Figure 133: Datamonitor drug assessment summary for Nexplatin in SCLC,
2007
- Figure 134: Incidence and mortality from thyroid cancer in 2007 and
2015 across the seven major markets
- Figure 135: Summary of unmet needs in the thyroid cancer market
- Figure 136: Phase II results investigating axitinib in thyroid cancer
patients refractory or unsuitable for radio-iodine therapy
- Figure 137: Axitinib sales forecast for thyroid cancer, 2007-16 ($m)
- Figure 138: Datamonitor drug assessment summary for axitinib in
thyroid cancer, 2007
- Figure 139: Datamonitor drug assessment summary of pipeline molecular
targeted therapies in development for hematological malignancies, 2007
|
Related Report
|
View Cart
